Immuron Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the year ended 30 June 2025 Previous period: For the year ended 30 June 20

calculation of net tangible assets excludes right-of-use assets arising from AASB 16 Leases.

Explanation of results

reported loss after tax of the current financial year of $5,253,209 (2024: $6,936,957) is after fully expensing the company's research

and development expenditure of $3,597,296 incurred during the year (2024: $5,375,461). Of which, $146,252 (2024: $2,599,458) was funded

by the R&D grant from Medical Technology Enterprise Consortium (MTEC).

revenue from contracts with customers for the year was $7,287,002, which is an increase of 48.6% from the prior financial year (2024:

$4,902,865), primarily due to the sales increase in the Australian and North American markets for Travelan . We anticipate that revenues

from sales of our Travelan product will continue to increase in the future.

at 30 June 2025, the company's cash position was $2,830,526 (30 June 2024: $11,657,315). The company had trade and other receivables

of $1,888,370 (30 June 2024: $1,387,573). This receivables amount includes future receivables from the Australian Government under the

R&D Tax Incentive program. The company had other current assets of $3,486,744 (30 June 2024: $96,841). This other current assets

amount includes a 90-day fixed term deposit of $3,036,278 (30 June 2024: Nil), which matured on 27 July 2025.

preliminary final report follows, with the further details to be included in the audited financial statements to be released by 30 September

dividends have been paid or declared by the company for the current financial year. No dividends were paid for the previous financial

Changes in controlled entities

have been no changes in controlled entities during the year ended 30 June 2025.

Details of associates and joint venture entities

at 30 June 2025, Immuron has a 23.61% interest in Ateria. Immuron is deemed to have significant influence over Ateria.

financial statements of Immuron Limited (the Group') are currently in the process of being audited. The audited financial statements

along with the independent auditor report for the year end 30 June 2025 will be provided in the due course.

Consolidated statement of profit or loss and other comprehensive income

the year ended 30 June 2025

above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

statement of financial position

above consolidated statement of financial position should be read in conjunction with the accompanying notes

statement of changes in equity

the year ended 30 June 2025

above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

statement of cash flows

the year ended 30 June 2025

above consolidated statement of cash flows should be read in conjunction with the accompanying notes

to the consolidated financial statements

Revenue from contract with customers

Group derives revenue from the transfer of hyperimmune products at a point in time in the following major product lines and geographical

Fair value of R&D tax incentive

Group's research and development (R&D) activities are eligible under an Australian government tax incentive for eligible expenditure.

Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts

are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be

reliably measured. For the year ended 30 June 2025, the Group has included an item in other income of $1,073,355 (2024: $764,981).

Trade and other receivables

as trade receivables

receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally

due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognised initially at the amount

of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value.

The Group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently

at amortised cost using the effective interest method.

to the consolidated financial statements

Trade and other receivables (continued)

amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive.

value of trade and other receivables

to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value.

Other current assets

Group entered into a 90-day fixed term deposit, which matured on 27 July 2025. Term deposits are presented as Other Current Assets as

they are not considered highly liquid instruments readily convertible to cash and cash equivalents. The deposit was held to maturity

in accordance with the Group's investment policy.

of each type of share

shares entitle the holder to participate in dividends and the proceeds on winding up of the company in proportion to the number of shares

held. On a show of hands every holder of ordinary shares present at a meeting or by proxy, is entitled to one vote upon a poll every

holder is entitled to one vote per share held. The ordinary shares have no par value.

to the consolidated financial statements

share-based payment reserve records items recognised as expenses on valuation of share options and warrants issued to key management

personnel, other employees and eligible contractors.

currency translation

differences arising on translation of foreign controlled entities are recognised in other comprehensive income as described in note and

accumulated in a separate reserve within equity.

to the consolidated financial statements

Share-based payments

rights which can be settled in shares, were granted to key management personnel and employees during the year. The expense for the year

ended 30 June 2025 was $239,488. The performance rights are based on non-market weighted key performance indicators (KPIs) and have been

expensed over the service period, based on the probability the KPIs being achieved. The performance rights are expected to vest between

were approved at the Annual General Meeting, held on 18 November 2024 for Prof. Ravi Savarirayan and Mr. Daniel Pollock of 1,000,000

each. The option exercise price is $0.145 and they have an expiry date of 20 August 2028. The expense for the year was $34,952.

were granted to Dr. Jeanette Joughin on 19 June 2024 but were subject to shareholder approval obtained on 18 November 2024. The expense

of $20,632 recorded in the year includes an adjustment for the revised estimate of fair value on the grant date of 18 November 2024.

value is determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the award, security

price at grant date, expected volatility, expected dividend yield and the risk-free interest rate.

model inputs for the options granted during the year:

Events after the reporting period

The Market Capital Raising

July 2025, Immuron Limited (ASX: IMC), raised gross proceeds of USD$1,822,322 (AUD$2,809,177) through an At The Market Facility comprising

34,260,960 shares at an average issue price of of USD$0.053 (AUD$0.082) per share.